FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2029590939> ?p ?o ?g. }

• W2029590939 endingPage "884" @default.
• W2029590939 startingPage "879" @default.
• W2029590939 abstract "Background 131I-metaiodobenzylguanidine (MIBG) produces a 37% response rate in relapsed/refractory neuroblastoma, and could be used to improve remission status prior to myeloablative chemotherapy with autologous stem cell transplant (ASCT). The purpose of our report was to evaluate safety and response with MIBG therapy followed by myeloablative busulfan and melphalan (BuMel) with ASCT in patients with refractory neuroblastoma. Methods Retrospective chart review was done on patients treated with MIBG (18 mCi/kg) on Day 1 and ASCT on Day 14. Six to eight weeks after MIBG, patients without progressive disease received IV busulfan on Days −6 to −2 (target Css 700–900), melphalan (140 mg/m2 IV) on Day −1, and ASCT on Day 0. Response and toxicity were evaluated after MIBG and again after myeloablative therapy. Results Eight patients completed MIBG/ASCT followed by BuMel/ASCT. MIBG was well tolerated, with Grade 3 or 4 non-hematologic toxicity limited to one patient with sepsis. Grade 3 mucositis occurred in six patients after BuMel/ASCT. One patient developed sinusoidal obstructive syndrome (SOS) and died 50 days post-ASCT following myeloablative conditioning. All patients engrafted neutrophils (median 16.5 days) and platelets (median 32 days) after BuMel, excluding the patient with SOS. After all therapy, there were three complete, two partial, and one minor response in seven evaluable patients. Conclusions MIBG at doses up to 18 mCi/kg can be safely administered 6 weeks prior to a BuMel consolidative regimen for refractory neuroblastoma. Preceding MIBG did not impair engraftment following BuMel. This regimen is being further evaluated in a Children's Oncology Group (COG) trial. Pediatr Blood Cancer 2013; 60: 879–884. © 2012 Wiley Periodicals, Inc." @default.
• W2029590939 created "2016-06-24" @default.
• W2029590939 creator A5001066329 @default.
• W2029590939 creator A5001767007 @default.
• W2029590939 creator A5003247873 @default.
• W2029590939 creator A5017840054 @default.
• W2029590939 creator A5051711134 @default.
• W2029590939 creator A5062864769 @default.
• W2029590939 creator A5078500931 @default.
• W2029590939 creator A5090486615 @default.
• W2029590939 date "2012-09-28" @default.
• W2029590939 modified "2023-10-14" @default.
• W2029590939 title "¹³¹I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma" @default.
• W2029590939 cites W1825707388 @default.
• W2029590939 cites W1877527541 @default.
• W2029590939 cites W1894683927 @default.
• W2029590939 cites W1962389813 @default.
• W2029590939 cites W1964456895 @default.
• W2029590939 cites W1967988534 @default.
• W2029590939 cites W1986200234 @default.
• W2029590939 cites W1993954120 @default.
• W2029590939 cites W2026077983 @default.
• W2029590939 cites W2070550035 @default.
• W2029590939 cites W2096398040 @default.
• W2029590939 cites W2098908781 @default.
• W2029590939 cites W2113902126 @default.
• W2029590939 cites W2118171008 @default.
• W2029590939 cites W2121955260 @default.
• W2029590939 cites W2130465135 @default.
• W2029590939 cites W2131352716 @default.
• W2029590939 cites W2139248078 @default.
• W2029590939 cites W2207035255 @default.
• W2029590939 cites W2317690033 @default.
• W2029590939 cites W2323995621 @default.
• W2029590939 cites W2327522594 @default.
• W2029590939 cites W2334750353 @default.
• W2029590939 cites W4211012683 @default.
• W2029590939 cites W4253467635 @default.
• W2029590939 doi "https://doi.org/10.1002/pbc.24351" @default.
• W2029590939 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23024113" @default.
• W2029590939 hasPublicationYear "2012" @default.
• W2029590939 type Work @default.
• W2029590939 sameAs 2029590939 @default.
• W2029590939 citedByCount "47" @default.
• W2029590939 countsByYear W20295909392013 @default.
• W2029590939 countsByYear W20295909392014 @default.
• W2029590939 countsByYear W20295909392015 @default.
• W2029590939 countsByYear W20295909392016 @default.
• W2029590939 countsByYear W20295909392017 @default.
• W2029590939 countsByYear W20295909392018 @default.
• W2029590939 countsByYear W20295909392019 @default.
• W2029590939 countsByYear W20295909392020 @default.
• W2029590939 countsByYear W20295909392021 @default.
• W2029590939 countsByYear W20295909392022 @default.
• W2029590939 countsByYear W20295909392023 @default.
• W2029590939 crossrefType "journal-article" @default.
• W2029590939 hasAuthorship W2029590939A5001066329 @default.
• W2029590939 hasAuthorship W2029590939A5001767007 @default.
• W2029590939 hasAuthorship W2029590939A5003247873 @default.
• W2029590939 hasAuthorship W2029590939A5017840054 @default.
• W2029590939 hasAuthorship W2029590939A5051711134 @default.
• W2029590939 hasAuthorship W2029590939A5062864769 @default.
• W2029590939 hasAuthorship W2029590939A5078500931 @default.
• W2029590939 hasAuthorship W2029590939A5090486615 @default.
• W2029590939 hasConcept C121332964 @default.
• W2029590939 hasConcept C126322002 @default.
• W2029590939 hasConcept C126894567 @default.
• W2029590939 hasConcept C141071460 @default.
• W2029590939 hasConcept C142424586 @default.
• W2029590939 hasConcept C143998085 @default.
• W2029590939 hasConcept C2776694085 @default.
• W2029590939 hasConcept C2776715637 @default.
• W2029590939 hasConcept C2777408962 @default.
• W2029590939 hasConcept C2778496288 @default.
• W2029590939 hasConcept C2778684742 @default.
• W2029590939 hasConcept C2779050716 @default.
• W2029590939 hasConcept C2780611847 @default.
• W2029590939 hasConcept C2780775027 @default.
• W2029590939 hasConcept C2781413609 @default.
• W2029590939 hasConcept C2911091166 @default.
• W2029590939 hasConcept C54355233 @default.
• W2029590939 hasConcept C71924100 @default.
• W2029590939 hasConcept C81885089 @default.
• W2029590939 hasConcept C86803240 @default.
• W2029590939 hasConcept C87355193 @default.
• W2029590939 hasConceptScore W2029590939C121332964 @default.
• W2029590939 hasConceptScore W2029590939C126322002 @default.
• W2029590939 hasConceptScore W2029590939C126894567 @default.
• W2029590939 hasConceptScore W2029590939C141071460 @default.
• W2029590939 hasConceptScore W2029590939C142424586 @default.
• W2029590939 hasConceptScore W2029590939C143998085 @default.
• W2029590939 hasConceptScore W2029590939C2776694085 @default.
• W2029590939 hasConceptScore W2029590939C2776715637 @default.
• W2029590939 hasConceptScore W2029590939C2777408962 @default.
• W2029590939 hasConceptScore W2029590939C2778496288 @default.
• W2029590939 hasConceptScore W2029590939C2778684742 @default.
• W2029590939 hasConceptScore W2029590939C2779050716 @default.
• W2029590939 hasConceptScore W2029590939C2780611847 @default.

• next